alexa Sensitivity versus Specificity in the Evaluation of Adv
ISSN: 2574-0407

Medical Safety & Global Health
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)


Sensitivity versus Specificity in the Evaluation of Adverse Event Data from Clinical Trial

Miao J*, Lai TL, Chen J and Heyse JF

Department of Statistics, Stanford University, CA, USA

*Corresponding Author:
Jing Miao
Department of Statistics
Stanford University
CA 94305, USA
Tel: +1650 7232300
E-mail: [email protected]

Received Date: May 11, 2017; Accepted Date: May 22, 2017; Published Date: May 30, 2017

Citation: Miao J, Lai TL, Chen J, Heyse JF (2017) Sensitivity versus Specificity in the Evaluation of Adverse Event Data from Clinical Trial. Med Saf Glob Health 6:133.

Copyright: © 2017 Miao J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



The evaluation of safety is an important part of clinical trials of pharmaceutical, biological, and vaccine products.In early phase trials, the evaluation is mostly exploratory with a focus primarily on serious adverse reactions to thecandidate product. In later phases of clinical development programs the safety profile is characterized more fully usinglarger numbers of patients. Unlike the evaluation of drug efficacy, the outcome of which is based on a single or acollection of prespecific hypotheses, the hypotheses to test to conclude a drug has potential safety burden is generallynot prespecified. The test and conclusion of potential safety issue of a drug are usually based on an arbitrary numberof reports of adverse events that have not been identified at the outset, which amounts to using observed data to test hypotheses that are generated by the same data.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version